Antagonistas de receptores de progesterona (PRA) y moduladores selectivos de receptores de progesterona (SPRM): aplicaciones en ginecología y obstetricia

Diana Marcela Suárez-Calderón, Ivonne Díaz-Yamal

Resumen


Dos décadas de estudio bioquímico, farmacológico y clínico han permitido la síntesis de antagonistas del receptor de la progesterona (PRA) y moduladores selectivos de receptores de progesterona (SPRM).El receptor de progesterona (PR) comparte la estructura de los receptores esteroideos  que al ser estimulados sufren un cambio conformacional y subsecuentemente activan la transcripción genética en un tejido específico. Dicho proceso depende, particularmente en el PR, del equilibrio existente entre coactivadores y correpresores que ya han sido identificados. El mifepristone ha sido catalogado como PRA, mientras que el asoprisnil es el clásico SPRM agonista-antagonista. Múltiples estudios experimentales y clínicos han evidenciado la utilidad de los PRA y los SPRM en escenarios clínicos tan comunes como la miomatosis uterina, la endometriosis, la terminación del embarazo y la anticoncepción. Sin embargo, aún no existe la molécula ideal y faltan estudios que respalden la seguridad y eficacia de mifepristone y asoprisnil a largo plazo. El objetivo del presente documento es revisar la farmacodinamia y usos clínicos de estos medicamentos en ginecología y obstetricia.

Palabras clave


receptores de progesterona; antiprogestina; mifepristone; asoprisnil; aborto; miomatosis; endometriosis; anticoncepción de emergencia

Texto completo:

PDF

Referencias


McPhail MK. The assay of progestins. J Physiol 1934;83:145-56.

Spitz I. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 2003; 68:981-93.

Evans RM. The steroid and thyroid hormone receptor super-family. Science 1988;240:889-95.

Fernández-Valdivia R, Mukherjee A, Mulac-Jericevic B, Conneely OM, DeMayo FJ, Amato P, et al. Revealing progesterone’s role in uterine and mammary gland biology: insights from the mouse. Semin Reprod Med 2005;23:22-37.

Spitz I. Clinical applications of progesterone receptor antagonists and selective progesterone receptor modulators. Endocrinologist 2005;15:391-400.

Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003;101:243-50.

Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003;18:61-8.

Bray J, Zhang Z, Winneker RC, Lyttle CR. Regulation of gene expression by PRA-910, a novel progesterone receptor modulator, in T47D cells. Steroids 2003; 68:995-1003.

Blithe D, Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M. Development of the selective progesterone receptor modulator CDB-2914forclinicalindications. Steroids 2003;68:1013-7.

Chwalisz K, Mattia-Goldberg K, Lee M, Elger W, Edmonds A. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. Fertil Steril 2004;82:S83-S84.

Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA. Mifepristone and misoprostol administred simultaneosly versus 24 hours for abortion: a randomized controlled trial. Obstet Gynecol 2007;109:885-94.

Guest J, Chien PF, Thomson MA, Kosseim ML. Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol. BJOG 2007;114:207-15.

Schreiber C, Creinin M. Mifepristone in abortion care. Semin Reprod Med 2005;23:82-91.

Bracken H, Ngoc NT, Schaff E, Coyaji K, Ambardekar S, Westheimer E, et al. Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion. Obstet Gynecol 2007;109:895-901.

Fisher M, Bhatnagar J, Guarner J, Reagan S, Hacker JK, Van Meter SH, et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 2005;353:2352-60.

Bartley J, Baird DT. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG 2002;109:1290-4.

Wagaarachchi PT, Ashok PW, Narvekar NN, Smith NC, Templeton A. Medical management of late intrauterine death using a combination of mifepristone and misoprostol. BJOG 2002;109:443-7.

Neilson JP. Mifepristone for induction of labour. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD002865.

Wing DA, Fassett MJ, Mishell DR. Mifepristone for preinduction cervical ripening beyond 41 weeks gestation: a randomized controlled trial. Obstet Gynecol 2000;96:543-8.

Hapangama DK, Brown A, Glasier A, Baird DT. Feasibility of administering mifepristone as a once a month contraceptive pill. Hum Reprod 2001;16:1145-50.

Verbost PM, Hanssen RG, Korver GH, Mulders TM. ORG 33628 and ORG 31710 to control vaginal bleeding in progestine-only contraceptive regimens. Semin Reprod Med 2005;23:101-11.

von Hertzen H, Van Look PF. Antiprogestine for contraception? Semin Reprod Med 2005; 23:92-100.

Hegele-Hartung C, Mootz U, Beier HM. Luteal control of endometrial receptivity and its modification by progesterone antagonists. Endocrinology 1992; 131:2446-60.

Han S, Sidell N. RU486-induced growth inhibition of human endometrial cells involves the nuclear factor kappa B signaling pathway. J Clin Endocrinol Metab 2003;88:713-9.

Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU486).Am J Obstet Gynecol 1998;178:1151-6.

Kim JJ, Wang J, Bambra C, Das SK, Dey SK, Fazleabas AT. Expression of cyclooxygenase-1 and -2 in the baboon endometrium during the menstrual cycle and pregnancy. Endocrinology 1999;140:2672-8.

Chwalisz K, Pérez MC, DeManno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrine Reviews 2006;26:423-38.

Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator in healthy premenopausal women. Hum Reprod 2005;20:1090-9.

Greb RR, Heikinheimo O, Williams RF, Hodgen GD, Goodman AL. Vascular endothelial growth factor in primate endometrium is regulated by oestrogenreceptor and progesterone-receptor ligands in vivo. Hum Reprod 1997;12:1280-92.

SteinauerJ, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103:1331-6.

Zeng C, Gu M, Huang H. A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone. Zhonghua Fu Chan Ke Za Zhi 1998;33:490-2.

Chwalisz K, DeManno D, Garg R, Larsen L, Mattia-Goldberg C, Stickler T. Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin Reprod Med 2004;22:113-9.

Goyeneche A, Caron R, Telleria C. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res 2007;13:3370-9.

Koiristo-Korander R, Leminen A, Heikinheimo O. Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma. Obstet Gynecol 2007;109:512-4.


comments powered by Disqus

Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM




Copyright (c) 2016 Revista Colombiana de Obstetricia y Ginecología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

ISSN Impreso       0034-7434 

ISSN Electrónico   2463-0225

https://doi.org/10.18597/issn.0034-7434